ArticleRespiratory research2026
Identifying molecular signatures of parapneumonic effusion reveals HMGB2 as the disease progression biomarker.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParapneumonic effusion (PPE) exacerbation is associated with high morbidity and mortality in pneumonia patients. However, the molecular signatures underlying the progression and severity of PPE remain poorly understood. We therefore employed whole-transcriptome profiling to comprehensively characterize the molecular landscape associated with PPE exacerbation and its clinical manifestations.
methodsIn the discovery cohort, 26 PPE patients underwent capture-based targeted RNA sequencing and were stratified by disease severity into non-severe PPE (UPPE, n = 9) and severe PPE (n = 17), comprising CPPE (n = 12) and empyema (n = 5). Bioinformatic functional annotation was performed to delineate gene expression signatures associated with disease progression from non-severe to severe PPE. Integrated analyses of the transcriptome and secretome of pleural effusions identified high-mobility group box 2 (HMGB2) as a novel biomarker for severe PPE. In the validation cohort, 220 patients with different pleural effusion etiologies were enrolled for enzyme-linked immunosorbent assay (ELISA) analysis to evaluate HMGB2 levels. The functional relevance of HMGB2 in PPE progression was characterized in neutrophils and macrophages.
resultsIn pneumonia patients, severe PPE was associated with higher expression of 232 genes and lower expression of 212 genes compared with non-severe PPE. Upregulated gene signatures associated with disease progression in severe PPE were enriched in neutrophil degranulation, glycolysis/gluconeogenesis, HIF-1 signaling, and inflammatory response pathways. Elevated HMGB2 levels in severe PPE enabled accurate discrimination from other pleural effusion cases, with an AUC of 0.93. In vitro infection with Streptococcus pneumoniae significantly increased HMGB2, IL1β, and IL8 expression in neutrophils and macrophages. Moreover, HMGB2 overexpression enhanced NF-κB activation as well as IL-1β and IL-8 levels in PGN-stimulated macrophages. These results suggest that HMGB2 regulates IL-1β and IL-8 via the NF-κB signaling pathway.
conclusionsOur study delineates molecular signatures driving PPE exacerbation and highlights HMGB2 as a novel biomarker and therapeutic target with potential to prevent severe PPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.